title: How many patients might receive thrombolytic therapy in the light of the ECASS-3 and IST-3 data?
authors.forename: Jan
authors.initials: J
authors.lastname: Bembenek
authors.forename: Adam
authors.initials: A
authors.lastname: Kobayashi
authors.forename: Peter
authors.initials: P
authors.lastname: Sandercock
authors.forename: Anna
authors.initials: A
authors.lastname: Czlonkowska
mesh_terms: D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006801:Humans; D020521:Stroke / Q000188:drug therapy*; D015912:Thrombolytic Therapy / Q000379:methods* / Q000706:statistics & numerical data*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator